StoxVilin Bio Med Limited
NSE: VILINBIO · Unclassified
Ask the data
Instant answers about Vilin Bio Med Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Revenue | 15.8 | 14.8 | 42.3 |
| EBITDA | 0.8 | 0.8 | 3.2 |
| Operating margin | 5.2% | 5.3% | 7.5% |
| Interest | 0.8 | 0.8 | 0.1 |
| Depreciation | 0.1 | 0.1 | 0.3 |
| Profit before tax | 0.2 | 0.3 | 2.8 |
| Tax | 0.1 | 0.1 | 0.9 |
| Net profit | 0.2 | 0.2 | 1.9 |
| EPS ₹ | 0.12 | 0.16 | 1.37 |
| Operating cash flow | -5.3 | -3.8 | 0.7 |
| Capex | 0.0 | 1.6 | 0.3 |
| Dividend paid | 0.0 | 0.0 | 0.0 |
| Total assets | — | 27.7 | 34.9 |
| Equity | — | 23.1 | 28.4 |
Half-yearly performance
last 6 half years · ₹ crore| H1 FY24 | H2 FY24 | H1 FY25 | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|---|---|
| Revenue | 7.7 | 8.2 | 4.5 | 10.3 | 9.7 | 32.6 |
| Operating profit | 1.4 | -0.6 | 0.4 | 0.4 | 0.3 | 2.9 |
| Operating margin | 18.2% | -7.0% | 9.4% | 3.6% | 3.5% | 8.8% |
| Other income | 0.1 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 |
| Interest | 0.4 | 0.4 | 0.4 | 0.4 | 0.1 | 0.0 |
| Depreciation | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 |
| Profit before tax | 1.0 | -0.8 | 0.1 | 0.1 | 0.2 | 2.6 |
| Tax | 0.3 | 0.0 | 0.0 | 0.1 | 0.0 | 0.9 |
| Net profit | 0.8 | -0.8 | 0.1 | 0.1 | 0.1 | 1.8 |
| EPS ₹ | 0.55 | 0.00 | 0.00 | 0.07 | 0.11 | 1.26 |
| Revenue YoY | — | — | -41.3% | 26.5% | 115.1% | 215.9% |
| Profit YoY | — | — | -84.4% | — | 25.0% | 1680.0% |
Returns & margins
trailing-twelve-month, per half year| H2 FY24 | H1 FY25 | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|---|
| ROE | -0.2% | -3.0% | 1.0% | 1.1% | 6.8% |
| ROCE | 3.5% | 0.5% | 4.5% | 3.6% | 10.2% |
| Net margin | -0.3% | -5.5% | 1.5% | 1.3% | 4.6% |
| EBITDA margin | 5.2% | -1.2% | 5.3% | 3.6% | 7.6% |
| Debt / equity | 0.24 | 0.32 | 0.11 | 0.02 | 0.01 |
| Interest coverage | 1.28 | 0.18 | 1.35 | 1.67 | 41.57 |
| Asset turnover | 0.51 | 0.38 | 0.53 | 0.80 | 1.21 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '23 | SEP '24 | MAR '25 | SEP '25 | MAR '26 | |
|---|---|---|---|---|---|
| Share capital | 13.9 | 13.9 | 13.9 | 13.9 | 15.2 |
| Other equity / reserves | 9.5 | 9.0 | 9.1 | 9.3 | 13.1 |
| Total equity | 23.4 | 23.0 | 23.1 | 23.2 | 28.4 |
| Borrowings | 5.5 | 7.3 | 2.6 | 0.5 | 0.2 |
| Current liabilities | 7.2 | 10.3 | 4.6 | 1.7 | 6.4 |
| Non-current liabilities | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 |
| Total assets | 30.9 | 33.4 | 27.7 | 25.0 | 34.9 |
| Property, plant & equipment | 1.4 | 1.5 | 1.3 | 3.1 | 2.9 |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventories | 2.4 | 4.1 | 4.4 | 6.1 | 7.2 |
| Receivables | 11.3 | 6.7 | 6.3 | 5.5 | 16.0 |
| Cash & equivalents | 6.5 | 0.0 | 0.1 | 0.1 | 1.5 |
Cash flow
annual · ₹ crore · line = free cash flow| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Cash from operations | -5.3 | -3.8 | 0.7 |
| Cash from investing | 0.3 | -1.1 | -0.3 |
| Cash from financing | 11.0 | -1.1 | 1.0 |
| Capex | 0.0 | 1.6 | 0.3 |
| Free cash flow | -5.3 | -5.4 | 0.4 |
| Dividends paid | 0.0 | 0.0 | 0.0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Vilin Bio Med Limited | 83 | 54.55 | 43.1 | 2.93 | 6.8% |
StoxGud checklist: Bullish setup · 7/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Vilin Bio Med Limited?
Vilin Bio Med Limited (VILINBIO) closed at ₹54.55 on NSE on 05 Nov 2026.
What is the market cap of Vilin Bio Med Limited?
₹83 crore at the latest close.
What is the P/E ratio of Vilin Bio Med Limited?
43.1, on trailing-twelve-month earnings from its filings.
How fast is Vilin Bio Med Limited growing?
Vilin Bio Med Limited: Latest-half-year revenue is up 215.9% year on year, profit up 1,680.0%.
How profitable is Vilin Bio Med Limited?
On a trailing-twelve-month basis return on equity is 6.8%, return on capital employed 10.2%, operating margin 7.6%, net margin 4.6%.
How much debt does Vilin Bio Med Limited have?
Vilin Bio Med Limited is debt-free: debt to equity is 0.01 with borrowings of ₹0 cr against cash of ₹1 cr (balance sheet of 2026-03-31). Operating profit covers interest 41.6 times.
Financials parsed from Vilin Bio Med Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Half-yearly from H1 FY24, annual from FY24, balance sheet from Sep '23. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.